Recurrent Vulvovaginal Candidiasis: The Causative Agents, Clinical Signs and Susceptibility to Fluconazole in Gonabad City, Northeast Iran

Author(s): Mohammad Hassan Minooeianhaghighi, Marziyeh Sehatpour, Hossein Zarrinfar*, Tanuka Sen.

Journal Name: Current Women`s Health Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Recurrent vulvovaginal candidiasis (RVVC) is the second most common cause of genital tract infection in females. Excessive use of fluconazole and other azoles is likely to cause the emergence of the resistant species of Candida.

Objective: The purpose of this research was to identify Candida isolates from RVVC and the antifungal effect of fluconazole against them.

Methods: In this study, 152 patients with vulvovaginal candidiasis were evaluated for the RVVC form. The Candida isolates were purified using CHROMagar Candida and identified based on the nuclear ribosomal internal transcribed spacer (ITS1-ITS2 rDNA) sequence analysis by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The antifungal susceptibility of C. albicans isolates against fluconazole was determined according to document M27-A3.

Results: Out of 152 patients, 20 cases (13.2%) were identified as recurrent form. The frequencies of the Candida species among the patients with RVVC were C. albicans (n = 16, 80%), C. parapsilosis (n = 3, 15%) and C. tropicalis (n = 1, 5%). The most common clinical sign was vaginal discharge (60%). The mean minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of fluconazole against Candida isolates were 32 µg/mL and 64 µg/mL, respectively.

Conclusion: C. albicans was the dominant cause of RVVC. The Candida isolates showed relatively high resistance to fluconazole in vitro. Vaginal discharge was the most common clinical sign among patients with RVVC.

Keywords: Recurrent vulvovaginal candidiasis, gonabad, predisposing factors, fluconazole, PCR-RFLP.

[1]
Kumari V, Banerjee T, Kumar P, Pandey S, Tilak R. Emergence of non-albicans Candida among candidal vulvovaginitis cases and study of their potential virulence factors, from a tertiary care center, North India. Indian J Pathol Microbiol 2013; 56(2): 144-7.
[http://dx.doi.org/10.4103/0377-4929.118703] [PMID: 24056652]
[2]
Moreira D, Paula CR. Vulvovaginal candidiasis. Int J Gynaecol Obstet 2006; 92(3): 266-7.
[http://dx.doi.org/10.1016/j.ijgo.2005.12.007] [PMID: 16434042]
[3]
Špaček J, Buchta V, Jílek P, Förstl M. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 2007; 131(2): 198-202.
[http://dx.doi.org/10.1016/j.ejogrb.2006.03.009] [PMID: 16687200]
[4]
Chopra V, Marotta F, Kumari A, et al. Prophylactic strategies in recurrent vulvovaginal candidiasis: a 2-year study testing a phytonutrient vs. itraconazole. J Biol Regul Homeost Agents 2013; 27(3): 875-82.
[PMID: 24152852]
[5]
Fidel PL Jr. History and new insights into host defense against vaginal candidiasis. Trends Microbiol 2004; 12(5): 220-7.
[http://dx.doi.org/10.1016/j.tim.2004.03.006] [PMID: 15120141]
[6]
Alizadeh M, Kolecka A, Boekhout T, et al. Identification of Candida species isolated from vulvovaginitis using matrix assisted laser desorption ionization-time of flight mass spectrometry. Curr Med Mycol 2017; 3(4): 21-5.
[PMID: 29707675]
[7]
Kord Z, Fata A, Zarrinfar H. Molecular identification of Candida species isolated from patients with vulvovaginitis for the first time in Mashhad. Iranian J Obstet Gynecol Infertil 2017; 20(4): 50-7.
[8]
Khorsand I, Nehzag G, Ali M, Zarrinfar H, Fata A, Naseri A, et al. Frequency of variety of Candida species in women with candida vaginitis referred to clinical centers of Mashhad, Iran. Iranian J Obstet Gynecol Infertil 2015; 18(168): 15-22.
[9]
Ventolini G, Baggish M. Recurrent vulvovaginal candidiasis. Clin Microbiol Newsl 2006; 28(12): 93-5.
[http://dx.doi.org/10.1016/j.clinmicnews.2006.05.004]
[10]
Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39(1): 1-8.
[http://dx.doi.org/10.1128/AAC.39.1.1] [PMID: 7695288]
[11]
Sanglard D, Ischer F, Calabrese D, Micheli M, Bille J. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist Updat 1998; 1(4): 255-65.
[http://dx.doi.org/10.1016/S1368-7646(98)80006-X] [PMID: 16904408]
[12]
Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis 2009; 64(3): 354-6.
[http://dx.doi.org/10.1016/j.diagmicrobio.2009.03.021] [PMID: 19501794]
[13]
Mathema B, Cross E, Dun E, et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001; 33(5): E23-7.
[http://dx.doi.org/10.1086/322600] [PMID: 11477529]
[14]
Shokri H, Khosravi AR, Yalfani R. Antifungal efficacy of propolis against fluconazole-resistant Candida glabrata isolates obtained from women with recurrent vulvovaginal candidiasis. Int J Gynaecol Obstet 2011; 114(2): 158-9.
[http://dx.doi.org/10.1016/j.ijgo.2011.02.019] [PMID: 21669419]
[15]
Zarrinfar H, Kaboli S, Dolatabadi S, Mohammadi R. Rapid detection of Candida species in bronchoalveolar lavage fluid from patients with pulmonary symptoms. Braz J Microbiol 2016; 47(1): 172-6.
[http://dx.doi.org/10.1016/j.bjm.2015.02.001] [PMID: 26887241]
[16]
Wayne P. National Committee for Clinical Laboratory Standards Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard— NNCLS Document M27- A3, Clinical and Laboratory Standards Institute. 2008.
[17]
Vermitsky J-P, Self MJ, Chadwick SG, et al. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008; 46(4): 1501-3.
[http://dx.doi.org/10.1128/JCM.02485-07] [PMID: 18305136]
[18]
Akinbiyi AA, Watson R, Feyi-Waboso P. Prevalence of Candida albicans and bacterial vaginosis in asymptomatic pregnant women in South Yorkshire, United Kingdom. Outcome of a prospective study. Arch Gynecol Obstet 2008; 278(5): 463-6.
[http://dx.doi.org/10.1007/s00404-008-0593-8] [PMID: 18299865]
[19]
Mahmoudi Rad M, Zafarghandi A, Abbasabadi B, et al. Identification and comparison of etiologic agents in vulvovaginal candidiasis and recurrent vulvovaginal candidiasis by a differential medium. Resen Med 2010; 33(3): 189-94.
[20]
Nazeri M, Mesdaghinia E, Moravej SAR, Atabakhshiyan R, Soleymani F. Prevalence of vulvovaginal candidiasis and frequency of candida species in women. JMUMS 2012; 21(86): 254-62.
[21]
Habibian R, Jafarzadeh L, Shahriari K. Investigating the relationship between recurrent vulvovaginal candidiasis with predisposing factors and symptoms of disease. Shahrekord Univ Med Sci J 2013; 15(5): 38-46.
[22]
Jafari Z, Motamedi M, Jalalizand N, Shokoohi GR, Charsizadeh A, Mirhendi H. A comparison between CHROMagar, PCR-RFLP and PCR-FSP for identification of Candida species. Curr Med Mycol 2017; 3(3): 10-5.
[http://dx.doi.org/10.29252/cmm.3.3.10] [PMID: 29707668]
[23]
Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178(2): 203-11.
[http://dx.doi.org/10.1016/S0002-9378(98)80001-X] [PMID: 9500475]
[24]
Fan SR, Bai FY, Liao QP, Liu ZH, Li J, Liu XP. Genotype distribution of Candida albicans strains associated with different conditions of vulvovaginal candidiasis, as revealed by microsatellite typing. Sex Transm Infect 2008; 84(2): 103-6.
[http://dx.doi.org/10.1136/sti.2007.025700] [PMID: 17971371]
[25]
Darce Bello M, Gonzalez A, Barnabé C, Larrouy G. First characterization of Candida albicans by random amplified polymorphic DNA method in Nicaragua and comparison of the diagnosis methods for vaginal candidiasis in Nicaraguan women. Mem Inst Oswaldo Cruz 2002; 97(7): 985-9.
[http://dx.doi.org/10.1590/S0074-02762002000700010] [PMID: 12471425]
[26]
Cheng G, Yeater KM, Hoyer LL. Cellular and molecular biology of Candida albicans estrogen response. Eukaryot Cell 2006; 5(1): 180-91.
[http://dx.doi.org/10.1128/EC.5.1.180-191.2006] [PMID: 16400181]
[27]
Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Yazdani Cherati J, Mosayebi E. Isolation of different species of Candida in patients with vulvovaginal candidiasis from sari, iran. Jundishapur J Microbiol 2015; 8(4)e15992
[http://dx.doi.org/10.5812/jjm.8(4)2015.15992] [PMID: 26034533]
[28]
Malazy OT, Shariat M, Heshmat R, et al. Vulvovaginal candidiasis and its related factors in diabetic women. Taiwan J Obstet Gynecol 2007; 46(4): 399-404.
[http://dx.doi.org/10.1016/S1028-4559(08)60010-8] [PMID: 18182346]
[29]
Jamilian M, Mashhadi E, Sarmadi F, Ghaznavirad A. Frequancy of vulvovaginal candidiasis species in nonpregnant 15-50 years old women in spring 2005 in Arak. J Arak Univ Med Sci 2007; 10(2): 7-14.
[30]
Aalei B, Touhidi A. Prevalence of candida vaginits among symptomatic patients in Kerman. J Qazvin Univ Med Sci 2000; 4(1): 42-8.
[31]
Faraji R, Rahimi MA, Rezvanmadani F, Hashemi M. Prevalence of vaginal candidiasis infection in diabetic women. Afr J Microbiol Res 2012; 6(11): 2773-8.
[32]
Bayani M, Asghar Sefidgar S, Basirat Z, Haji Ahmadi M, Asgharzadeh S. Association of clinical symptoms and laboratory results in diagnoses of candida vaginitis. Majallah-i Danishgah-i Ulum-i Pizishki-i Babul 2014; 16(1): 50-5.
[33]
Sobel JD, Zervos M, Reed BD, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003; 47(1): 34-8.
[http://dx.doi.org/10.1128/AAC.47.1.34-38.2003] [PMID: 12499165]
[34]
Vakili L, Jafarpur M. The determination of vaginal candidiasis inwomen referred to Shahid Rajaei hospital in Tonekabon (2009-2010). Med Lab J 2011; 5(1): 1-7.
[35]
Tseng Y-H, Lee W-T, Kuo T-C. In-vitro susceptibility of fluconazole and amphotericin B against candida isolates from women with vaginal candidiasis in Taiwan. Yao Wu Shi Pin Fen Xi 2005; 13(1): 12-6.
[36]
Ozçelik B, Kaynak F, Cesur S, Sipahi B, Sultan N. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens. Jpn J Infect Dis 2007; 60(5): 302-4.
[PMID: 17881873]
[37]
Moallaie H, Verissimo C, Brandão J, Rosado L. The sensitivity and resistance of yeasts isolated from women with vulvovaginal candidiasis to common antifungal drugs using disc diffusion. J Sabzevar Univ Med Sci 2010; 16(4): 213-9.
[38]
Quindós G, Carrillo-Muñoz AJ, Arévalo MP, et al. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000; 46(6): 395-401.
[http://dx.doi.org/10.1159/000007320] [PMID: 11053905]
[39]
Shokohi T, Badali H, Amirrajab N, Ataollahi MR, Kouhpayeh SA, Afsarian MH. In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran. Curr Med Mycol 2016; 2(2): 34-9.
[PMID: 28681018]
[40]
Kim J-M, Park YJ. Probiotics in the prevention and treatment of postmenopausal vaginal infections. J Menopausal Med 2017; 23(3): 139-45.
[http://dx.doi.org/10.6118/jmm.2017.23.3.139] [PMID: 29354612]
[41]
Caruso S, Cianci S, Fava V, Rapisarda AMC, Cutello S, Cianci A. Vaginal health of postmenopausal women on nutraceutical containing equol. Menopause 2018; 25(4): 430-5.
[http://dx.doi.org/10.1097/GME.0000000000001061] [PMID: 29315133]
[42]
Vitale SG, Caruso S, Rapisarda AMC, Cianci S, Cianci A. Isoflavones, calcium, vitamin D and inulin improve quality of life, sexual function, body composition and metabolic parameters in menopausal women: result from a prospective, randomized, placebo-controlled, parallel-group study. Przegl Menopauz 2018; 17(1): 32-8.
[http://dx.doi.org/10.5114/pm.2018.73791] [PMID: 29725283]
[43]
Pino A, Giunta G, Randazzo CL, Caruso S, Caggia C, Cianci A. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. Microb Ecol Health Dis 2017; 28(1)1357417
[http://dx.doi.org/10.1080/16512235.2017.1357417] [PMID: 28959181]
[44]
Russo R, Karadja E, De Seta F. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Benef Microbes 2019; 10(1): 19-26.
[http://dx.doi.org/10.3920/BM2018.0075] [PMID: 30525953]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [46 - 51]
Pages: 6
DOI: 10.2174/1573404815666191104142813
Price: $65

Article Metrics

PDF: 13
HTML: 5
EPUB: 1
PRC: 1